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Abstract Charcot-Marie-Tooth disease type 1A (CMT1A)
and hereditary neuropathy with liability to pressure palsies
(HNPP) represent the most common heritable neuromuscular
disorders. Molecular diagnostics of CMT1A/HNPP diseases
confirm clinical diagnosis, but their value is limited to the
clinical course and prognosis. However, no biomarkers of
CMT1A/HNPP have been identified. We decided to explore
if the LITAF/SIMPLE gene shared a functional link to the
PMP22 gene, whose duplication or deletion results in
CMT1A and HNPP, respectively. By studying a large cohort
of CMT1A/HNPP-affected patients, we found that the LITAF
I92V sequence variant predisposes patients to an earlier age of
onset of both the CMT1A and HNPP diseases. Using cell
transfection experiments, we showed that the LITAF I92V
sequence variant partially mislocalizes to the mitochondria in
contrast to wild-type LITAF which localizes to the late
endosome/lysosomes and is associated with a tendency for
PMP22 to accumulate in the cells. Overall, this study shows
that the I92V LITAF sequence variant would be a good
candidate for a biomarker in the case of the CMT1A/HNPP
disorders.
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Introduction
Charcot-Marie-tooth disease type 1A (CMT1A) and heredi-
tary neuropathy with liability to pressure palsies (HNPP)
belong to the group of most common heritable neuromuscular
disorders caused by submicroscopic duplication or deletion of
the 17p11.2-p12 region, respectively [14, 10, 3], Chance et al.,
1993]. Clinical variability in CMT1A and HNPP is a well-
known phenomenon [11, 15]. Indeed, marked variability is
noted in monozygotic CMT twins when reference is made to
clinical and electrophysiological features [4]. Presently, the
genetic counseling of CMT1A/HNPP-affected patients is lim-
ited to the confirmation of clinical diagnosis and the estima-
tion of the recurrence risk of these disorders. However, while
clinical variability is a well-known phenomenon in the case of
both CMT1A and HNPP, no biological basis for it is known.
Thus, while the CMT1A/HNPP diagnosis may be precise,
molecular genetics do not seem to help in issues relating to
the prognosis or clinical course of these disorders.
It has been suggested that lipopolysaccharide-induced tu-
mor necrosis factor-alpha factor (LITAF) may play a signifi-
cant role in CMT. While patients who initially lacked muta-
tions to known genes were designated to the CMT1C subtype,
the molecular basis of the latter has recently been identified as
a mutation in LITAF [21]. Such LITAF mutations associated
with CMT, such as I92V, occur mostly in the C-terminus of
LITAF. The mechanism by which mutations in LITAF give
rise to the CMT1C disease phenotype remains unknown.
Although mutations in LITAF that cause CMT1C have been
shown to result in mislocalization of LITAF from the
endosome/lysosome to the mitochondria (Ferreira [7]), and
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these mutations result in defects in regulating endosomal
trafficking and signaling [9, 23].
The dosage of the peripheral myelin protein 22 (PMP22)
gene seems to be a critical factor where the clinical course of
CMT1A/HNPP is concerned. Thus, the number of copies of
the PMP22 gene has been shown to correspond with the
clinical course of neuropathy in laboratory transgenic animals
[18, 22]. Moreover, an experimental approach entailing the
reduced expression of the PMP22 gene resulted in an im-
proved clinical course of CMT in transgenic animals
(mice/rats) [19]. Given the potential role of PMP22 regulatory
sequences in the gene-dosage effect, we decided to analyze an
extended region of the 5′UTR sequence encompassing
5000 kb and the coding sequence of the PMP22 gene in
patients with CMT1A/HNPP (duplication/deletion of the
PMP22 gene). Unfortunately, we failed to detect any signifi-
cant variants within the PMP22 regulatory sequence that
could be responsible for the gene-dosage effect and the ob-
served clinical variability in the CMT1A/HNPP diseases [20].
Materials and methods
Reagents, cell lines, and antibodies
Baby green monkey kidney (BGMK) was obtained from the
American Type Culture Collection (ATCC; Manassas, VA).
BGMK cells were cultured in Dulbecco-modified Eagle’s
medium (DMEM; HyClone, Ottawa, ON) with 7 % fetal
bovine serum (FBS; HyClone), 2-mM L-glutamine, 100-U/
mL penicillin, and 100-μg/mL streptomycin, at 37 °C with
5 % CO2. The following antibodies/probes were used during
immunofluorescence: Lysotracker®DND-99 from Molecular
Probes (Burlington, ON), the 9E10 mouse and mouse myc
monoclonal antibody from Roche (dilution 1/100;
Indianapolis, IN), rabbit anti-FLAG (dilution 1/100;
Burlington, ON), and FITC/Cy3-conjugated goat anti-mouse
or anti-rabbit immunoglobulin G (IgG) from Jackson
ImmunoResearch Inc. (dilutions 1/100, 1/200 respectively;
West Grove, PA, anti-CD63 antibody from Invitrogen (dilu-
tion 1/100; Burlington, ON); and MitoTRACKER Red FM
from Molecular Probes (Burlington, ON). LITAF WT was
synthesized by GenScript (Piscataway, NJ). Myc-tag was
added to the N-terminus of the protein to facilitate imaging.
PMP22 was synthesized by Sino Biological Inc. (BC019040,
Beijing). The gene was pCMV/hygro and contained a flag-
tag.
Patients and genetic analysis
One hundred six patients affected with CMT were examined
by neurologists at the Neuromuscular Unit and Warsaw
Department of Neurology. Family trees of at least three
generations were constructed for all the patients. The clinical
diagnosis of CMT/HNPP was then confirmed in all patients
by means of electromyography examination (EMG). Patients
displaying symmetrical, generalized neuropathy involving
upper and lower limbs were included in this study. All mem-
bers of the CMT1A/HNPP-affected families gave their signed
informed consent for the study, which gained the approval of
the local Ethics Committee at Warsaw Medical University
(approval No. 120/2008.). The control group consists of 50
unaffected individuals. Genomic DNA was extracted from
peripheral blood lymphocytes using the salting-out procedure.
The duplication/deletion of the PMP22 gene was confirmed
using Real-Time PCR (Q-PCR) [1]. This was performed in the
context of a multiplex assay making use of two TaqMan
probes labeled with FAM (PMP22 gene) and VIC (human
serum albumin gene). The Q-PCR reaction was performed on
the ABI-7500 Real-Time PCR system (Applied Biosystems).
The relative dosage (RQ) of the PMP22 gene ranges from
0.700 to 1.090 in normal individuals (two copies of the
PMP22 gene), from 0.359 to 0.595 in HNPP patients (one
copy of the PMP22 gene), and from 1.176 to 2.324 in
CMT1A patients (three copy of the PMP22 gene) [5].
The three coding exons 2–4 of the LITAF gene were
amplified by PCR (primer sequences previously described
by [21]). The PCR products were sequenced directly using a
BigDyeTM Terminator Version 1.1 Ready Reaction Cycle
Sequencing kit on the ABI 3730/xl genetic analyzer
(Applied Biosystems). The LITAF gene sequence was ana-
lyzed by comparison with reference sequence NM_004862.3
(transcript variant 1).
Total RNA was isolated from peripheral blood lympho-
cytes using the TRIzol Reagent, in line with the instructions
from the manufacturer (Invitrogen).
RT-PCR reactions were carried out using a First Strand
cDNA Synthesis Kit (Fermentas), again in line with the man-
ufacturer’s instructions.
Statistical analysis
The data was presented as means±SD, medians, and ranges of
values [Table 1]. Differences in values assumed by the vari-
ables were assessed using the Mann–Whitney U test. The
p<0.05 level was considered statistically significant, data
being analyzed using the StatSoft statistical software package
version 5.
PCR and expression plasmids
LITAF WT and the I92V LITAF mutation were amplified
using a 50-μL PCR mixture containing 1× PCR buffer
(Invitrogen), 3.0-mM MgCl2 (Invitrogen), 0.2-mM forward
and reverse primers, and 2.5-U Taq DNA polymerase (5 U/
μL; Invitrogen). LITAF WT and mutations were used as
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template DNA for the following primers: 5′-ATGGAGCAGA
AACTGATTAGT-3′ (LITAF-forward), 5′-TACCAGTCT
TTGTAAGTTCC-3′ (LITAF-reverse). The cycling conditions
used were 94 °C for 30 s, 52 °C for 30 s, and 72 °C for 90 s for
30 cycles. The resulting PCR product was cloned into
pTARGET (Promega, Madison).
Sequencing
In order to confirm that transformation into cloning vectors
was performed correctly, and to identify potential LITAF
mutations, LITAF samples were prepared and sent for se-
quencing at the Robarts Institute (London, ON). Once se-
quencing was completed, data was analyzed using Codon
Aligner 4.0.4 (Centerville, MA).
Transfections
BGMK cells were grown to 70 % confluency and transfected
using a polyethylenimine (PEI) reagent. DNA (5 μl) was
diluted with 400 μl of serum-free DMEM. PEI was added in
a 4:1 ratio of PEI:DNA and left to incubate at room temper-
ature for 15 min. The transfection mix was then added to cells
along with fresh DMEM.
Immunofluorescence
In 24-h post-transfection, the cells were probed with
MitoTRACKERRed FMor LysoTRACKER then fixed using
3.7 % paraformaldehyde solution in phosphate buffer solution
(PBS) and permeabilized using a 0.1 % Triton X-100 solution
in PBS. Cells were blocked for 2 h at room temperature in
block buffer (5% bovine serum albumin (BSA) (w/v), 50-mM
Tris HCl (pH 7.4), 150-mMNaCl, 0.5 % NP-40 (v/v)) follow-
ed by several 5-min washes in wash buffer (1 % bovine serum
albumin (BSA) (w/v), 50-mM Tris HCl (pH 7.4), 150-mM
NaCl, 0.5 % NP- 40 (v/v)). Primary antibody diluted in wash
buffer was incubated on cells for 1 h at room temperature. The
primary antibody was removed following several 5-min
washes in wash buffer, and secondary antibody was diluted
in wash buffer and applied to cells. The secondary antibody
was left on cells for 1 h at room temperature in darkness before
removal with several 5-min washes in wash buffer. Cells were
mounted using VECTASHIELD (Vector Labs, Burlington,
ON), and fluorescence was detected using a Leica DM SP2
confocal microscope (Leica, Wetzlar, Germany). Images were
assembled using Adobe Photoshop CS4 (Adobe, San Jose,
CA). This process was repeated at least three times, and results
were analyzed using ImageJ by using the method described by
Burgess et al. [2].
Results
The I92V LITAF sequence variant predisposes patients to an
earlier age of onset of CMT1A and HNPP diseases
We found that the presence of I92V heterozygous substitution
in the LITAF gene is associated with an earlier age at onset of
CMT1A and HNPP diseases in the group of patients mani-
festing with CMT1A/HNPP after 10 years of age. In this
group of patients, we found a statistically significant associa-
tion (p=0.005 and p=0.023) for CMT1A and HNPP, respec-
tively [Table 1].
In general, the CMT1A and HNPP-affected patients har-
boring the I92V mutation manifest with CMT1A/HNPP
13 years earlier than the patients without I92V sequence
variant.
The statistically significant association was not detected for
the CMT1A/HNPP patients with early age at onset (before
10 years of age) harboring Ile92Val mutation.
We have also taken into consideration other features of the
CMT1A/HNPP phenotype (lower and upper limb weakness,
Table 1 Correlation between CMT1A/HNPP age at onset (AOE) and
I92V mutation within LITAF gene
Patients Parameters Age at onset (years) p value
HNPP>10+I92V mean±SD (n) 18±6 (16) 0023
median 17.5
min-max 11–32





mean±SD (n) 23±10 (15) 0005
median 20
min-max 11–47
CMT1A>10 mean±SD (n) 36±14 (30)
median 35.5
min-max 13–67
CMT1A<10+I92V mean±SD (n) 4.8±3.2 (11) 0.963
median 4
min-max 1.3–10
CMT1A<10 mean±SD (n) 5.4±4.4 (7)
median 3
min-max 1.5–10
HNPP>10+I92V patients with HNPPwith AOE after 10 year of life with
sequence variant Ile92Val in LITAF gene,HNPP>10 patients with HNPP
with AOE after 10 year of life without sequence variant Ile92Val in LITAF
gene, CMT1A>10+I92V patients with CMT1Awith AOE after 10 year
of life with sequence variant Ile92Val in LITAF gene, CMT1A>10 pa-
tients with CMT1A with AOE after 10 year of life without sequence
variant Ile92Val in LITAF gene, CMT1A<10+ I92V patients with
CMT1Awith AOE before 10 year of life with sequence variant Ile92Val
in LITAF gene, CMT1A<10 patients with CMT1A with AOE before
10 year of life with sequence variant Ile92Val in LITAF gene
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foot deformity requiring surgery, presence of deep tendon
reflexes or sensory disturbances). No statistically significant
associations have been found for clinical parameters of
CMT1A/HNPP and the presence of I92V LITAF mutation.
To conclude, within numerous clinical parameters of
CMT1A/HNPP phenotypes, only age at onset has been shown
to be associated with the presence of I92V mutation in the
group of older patients (after 10 years of age).
The I92V LITAF sequence variant mislocalizes
to the mitochondria
Since we observed differences in age of onset of
CMT1A and HNPP in patients depending on the occur-
rence of the LITAF I92V sequence variant, we were
interested to see if the I92V LITAF mutant is found
in the same subcellular location as the WT LITAF. To
further explore the relocation of LITAF, we transfected
into BGMK cells either wild-type LITAF or I92V. We
observed that WT LITAF co-localizes with the lysosom-
al marker CD63, suggesting that WT LITAF is normally
present in the lysosomes (Fig. 1a). Next, we analyzed
the localization of the I92V mutant and found that a
portion of the I92V protein is localized to the lysosome
(Fig. 1b) and a portion localizes with the mitochondria
(Fig. 1b). This data suggests that a portion of the I92V
mutant is mislocalized in the cell.
LITAF effects protein levels of PMP22
LITAF has been implicated in protein degradation [9, 23]
while duplication of PMP22 results in CMT1A ([14], Lupski
et al., 1991. Since mutations in LITAF and PMP22 produce a
more severe form of CMT, we wondered if LITAF might be
involved in regulating the amount of PMP22 protein. We co-
transfected into BGMK cells either wild-type LITAF or I92V
with flag-tag PMP22. We observed a 41 % increase in fluo-
rescence when the cells were co-transfected with PMP22 and
I92V compared to cells co-transfected with PMP22 and WT
(Fig. 2), supporting the idea that LITAF may play a role in the
degradation of PMP22.
Discussion
In the present study, we show that the I92V sequence
variant in addition to PMP22 mutations predispose pa-
tients to an earlier age of onset of both CMT1A/HNPP
diseases. The I92V LITAF sequence variant has not
been considered a biomarker of CMT1A/HNPP.
Nevertheless, in a single CMT1A family study, the
I92V sequence variant has been shown to contribute to
a more severe CMT1A phenotype [12]. Similarly, Scelsa
and co-workers reported an association between the
I92V sequence variant and familiar inflammatory demy-
elinating polyneuropathy in a single family [17].
The I92V sequence variant occurs in different ethnic
groups with a relatively high frequency in the healthy
individuals. In our study, the I92V mutation was found
in 47 % of CMT1A-affected patients and 54 % HNPP
patients [Table 2]. Recently, in a small group of patients
manifesting with early-onset HNPP, the I92V sequence
variant within the LITAF gene was again found to be
present [13]. Thus, CMT1A patients with an increased
gene dosage of PMP22 and the I92V mutation may
manifest CMT1A symptoms earlier than patients with
a wild-type LITAF protein.
Interestingly, a statistically significant effect of the
I92V sequence variant on CMT1A/HNPP phenotype
has only been found in the group of patients
Fig. 1 LITAF mutants show different location fromWT LITAF. BGMK
cells were transiently transfected with myc-tagged WT LITAF and
Ile92Val. In 24-h post-transfection, the cells were a fixed and perme-
abilized before indirect immunofluorescence was used to detect LITAF
using anti-myc antibody (green), and lysosomes were visualized using
anti-CD63 (red) or b stained with MitoTRACKER (red) prior to the use
of indirect immunofluorescence with anti-myc antibodies (green) to
detect LITAF. Nuclei were visualized using differential interference con-
trast (DIC), and images were captured using a scanning confocal
microscope
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manifesting CMT1A/HNPP disease after 10 years of
age. We therefore cannot preclude the action on the part
of other modifying genetic factors in the case of a
group of younger patients with a more severe, early
age at onset clinical course for CMT1A/HNPP. In other
words, PMP22 gene dosage regulated by LITAF activity
is not the single, exclusive molecular mechanism
influencing the severity of CMT1A. While our study
also analyzed other parameters of CMT1A, the only
statistically significant result obtained was the correla-
tion between age at onset and the I92V mutation within
the LITAF gene.
Given the primary role of LITAF protein in the
degradation of PMP22, the mislocalization of LITAF
from lysosomes to mitochondria may be associated with
a less effective degradation of PMP22 protein. Since
gene dosage is considered crucial to CMT1A severity,
the decrease of LITAF within lysosomes may be a key
factor in molecular pathogenesis of CMT1A. We there-
fore hypothesized that the LITAF gene might play a role
in the regulation of PMP22 gene dosage. In this study,
we explored the effect of I92V LITAF on PMP22 level
within the cell and found through immunofluorescence
that when BGMK cells are co-transfected with PMP22
and I92V, there is a tendency for PMP22 to accumulate
in the cell, suggesting that LITAF plays a role on
PMP22 regulation.
In summary, our results indicate that the LITAF I92V
sequence variant is associated with an earlier age of
onset of the CMT1A/HNPP diseases and may be con-
sidered a genetic modifier of clinical variability. To
conclude with respect to the Polish population at least,
the I92V LITAF sequence variant may be considered a
genetic modifying factor.
Fig. 2 LITAF 192 V causes
changes in the amount of PMP22
protein. BGMK cells were
transiently transfected with a, b
FLAG-tagged PMP22 and b
myc-tagged I92V. LysoTracker or
MitoTracker was applied to live
cells 24 h post-infection, and cells




was detected using anti-myc




interference contract (DIC). All
images were taken using a laser
scanning confocal microscope







CMT (patients without duplication
or deletion of PMP22 gene)
Control group Reference
USA ND ND 46 % (n=192) 18 % (n=94) [16]
France ND ND 38 % (n=35) 26 % (n=50) [8]
Denmark ND ND na 16.2 % [12]
Serbia ND ND na na (n=75) [6]
Poland 47 % 54 % 37.6 % (n=49) 22 % (n=50) This study
M (n=38) F (n=31) M (n=27) F (n=10)
ND not done, na data not available, M male, F female
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